Efficiency comparison of an isoeugenol-derivated compound, eugenosedin-A, with glibenclamide and pioglitazone in protecting cardiovascular dysfunction of diabetic SHR. Issue 5 (4th May 2023)

• Record Type: Journal Article
• Authors: Hao, Chi-Long; Lin, Hui-Li; Cheng, Pei-Wen; Tu, Yi-Chen; Yeh, Bor-Chun; Wu, Bin-Nan; Shen, Kuo-Ping
• Is Part Of: Journal of Asian natural products research. Volume 25:Issue 5(2023)
• Page Start: 471
• Page End: 483
• Publication Date: 2023-05-04
• Subjects: Eugenosedin-A -- glibenclamide -- pioglitazone -- diabetes mellitus -- cardiovascular dysfunction; Materia medica -- Asia -- Periodicals; Pharmacognosy -- Asia -- Periodicals; Medicinal plants -- Asia -- Periodicals; Medicine, Oriental -- Asia -- Periodicals; 615.321095
• DOI: 10.1080/10286020.2022.2096597
• Languages: English
• ISSNs: 1028-6020

Abstract

Abstract: This study was to investigate three agents possible protective effect against DM-induced cardiovascular dysfunction in spontaneously hypertensive rats (SHR). Control group was fed normal diet, DM group was injected with STZ/NA and fed high fat diet (HFD), and treatment groups were given STZ/NA, fed HFD, and then oral gavaged with eugenosedin-A (Eu-A), glibenclamide (Gli), or pioglitazone (Pio) 5 mg/kg/per day for 4-week, respectively. Eu-A, Gli, and Pio clearly ameliorated the changes of body weight, cardiac weight, and the biochemical parameters, cardiovascular disorders and inflammation. Like Gli and Pio, Eu-A may be effectively to control DM and the cardiovascular dysfunction. Graphical Abstract: UF0001